Trade Talis Biomedical Corporation - TLIS CFD

Talis Biomedical Corporation Company profile

About Talis Biomedical Corp

Talis Biomedical Corporation. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The Company is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The Company is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Talis Biomedical Corp revenues decreased 25% to $8.2M. Net loss increased from $91.1M to $192M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$3.88 to -$7.30.